Drugs / hdmASIT+TM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03094845 | Sep 2016 → Jan 2017 | house allergic alveolitis | ASIT Biotech S.A. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hdmASIT+TM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03094845 ↗ |
| Route | Subcutaneous | “Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously” NCT03094845 ↗ |